Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Patent
1995-06-06
1998-11-10
Housel, James C.
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
4242741, 4241841, G01N 3100, G01N 3348, A61K 4900
Patent
active
058339469
ABSTRACT:
Aspartyl protease inhibitors such as pepstatin A have been found to prevent dissemination of Candida species across an epithelial barrier in mammals. Accordingly, a method for reducing adverse biological effects of dissemination of Candida species in an immunosuppressed mammal comprises administering prophylactically to the mammal an effective amount of an inhibitor of an aspartyl protease. Also, a method for identifying medicaments useful for preventing or treating systemic Candidiasis comprises treating test and control groups of immunosuppressed mammals with vehicle comprising a potential medicament, and with vehicle alone, respectively; administering to the test and control groups of mammals at least one Candida species, via the airways, at a time subsequent to the treating step if prophylactic medicaments are to be evaluated, but at a time prior to initiation of the treating step if therapeutic medicaments are to be evaluated; monitoring for a biological response of the test and control groups of mammals to the treating and administering steps; and comparing the biological response of the test and control groups of mammals over time.
REFERENCES:
patent: 3740319 (1973-06-01), Umezawa et al.
patent: 3784686 (1974-01-01), Miller et al.
patent: 3840516 (1974-10-01), Umezawa et al.
patent: 3869347 (1975-03-01), Umezawa et al.
patent: 3873681 (1975-03-01), Miller
patent: 3906085 (1975-09-01), Miller
patent: 3975366 (1976-08-01), Umezawa et al.
patent: 4091093 (1978-05-01), Kojima et al.
patent: 4185096 (1980-01-01), Castro et al.
patent: 4206283 (1980-06-01), Kojima et al.
patent: 4339439 (1982-07-01), Buyniski et al.
patent: 4348386 (1982-09-01), Kojima et al.
patent: 4663167 (1987-05-01), Lopez-Berestein et al.
patent: 4725580 (1988-02-01), Wagnon et al.
patent: 4737488 (1988-04-01), Lockhoff et al.
patent: 4746648 (1988-05-01), Wagnon et al.
patent: 4761402 (1988-08-01), Williams
patent: 4840935 (1989-06-01), Wagnon et al.
patent: 4900722 (1990-02-01), Williams
patent: 4978654 (1990-12-01), Lopez-Berestein et al.
patent: 5120718 (1992-06-01), Goldman et al.
Morrison et al, Infect. & Immun. , May 1993, pp. 2030-2036.
Fusek et al, Adv Exp Medicine & Bio, 1995, pp. 489-500, v362.
de Repentigny et al, Infect & Immun., Nov. 1992, pp. 4907-4914.
Tumminello et al, Med Res Reviews, v 13, No. 2, pp. 199-208, 1993.
Karyotakis et al, JInfectious Diseases, 1993, 168:1311-3.
Borg et al, Infect. and Immun., Mar. 1988, pp. 626-631.
Cole et al, J Med Vet Myrol, 1989, 27(6) pp. 363-380.
Zotter et al, Dermatol Monatsschr, 1990, 176(2-3) pp. 189-198 (abst.).
Cutler, Putative Virulence Factors of Candida Albicans, Annu. Rev. Microbiol. 45, 187-218 (1991).
Togni et al., Acid Proteinase Secreted by Candida Tropicalis: Virulence in Mice of a Proteinase Negative Mutant, J. Med. Vet. Mycol., 32, 257-265 (1994).
van Etten, et al. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of sytemic candidosis in immunocompetent and leucopenic mice, J. Antimicrob. Chemotherapy, 32, 732-739 (1993).
Tsuobi, et al., A Specific Inhibitor of Keratinolytic Proteinase from Candida albicans Could Inhibit the Cell Growth of C. Albicans, J. Invest. Dermatol., 85, 438-440 (1985).
Zotter, et al., The effect of pepstatin A on Candida albicans infection in mice, Dermatol. Mon.schr., 176, 189-198 (1990).
Ruchel, et al., Modulation of Experimental Systemic Murine Candidosis by Intravenous Pepstatin, Zbl. Bakt., 273, 391-403 (1990).
Ross, et al., The secreted aspartate proteinase of Candida albicans: physiology of secretion and virulence of a proteinase-dificient mutant, J. Gen. Microbiology, 136, 687-694 (1990).
Field, et al., Persistence and Spread of Candida albicans After Intragastric Inoculation of Infant Mice, Infection and Immunity, 31, 783-791 (1981).
Ghannoum, et al., Correlative relationship between proteinase production, adherence and pathogenicity of various strains of Candida albicans, J. Med. and Vet. Mycology, 24, 407-413 (1986).
Toshitsugu Nakamura, Experimental pulmonary candidiasis in modified rabbits, Mycopathologia, 85, 129-144 (1984).
Balish, et al., Colonization of Congenitally Athymic, Gnotobiotic Mice by Candida albicans, Applied and Environmental Microbiology, 47, 647-652 (1984).
Ekenna, et al., Factors Affecting Colonization and Dissemination of Candida albicans from the Gastrointestinal Tract of Mice, Infection and Immunity, 55, 1558-1563 (1987).
Pope, et al., Sytemic and Gastrointestinal Candidiasis of Infant Mice After Intragastric Challenge, Infection and Immunity, 25, 702-707 (1979).
Ray, et al., Comparative Production and Rapid Purification of Candida Acid Proteinase from Protein-Supplemented Cultures, Infection and Immunity, 58, 508-514 (1990).
Kwon-Chung, et al., Genetic Evidence for Role of Extracellular Proteinase in Virulence of Candida albicans, Infection and Immunity, 49, 571-575 (1985).
Kobayashi, et al., A Role of Secreted Proteinase of Candida albicans for the Invasion of Chick Chorio-Allantoic Membrane, Microbiol. Immunol., 33, 709-719 ( 1989).
El-Magharabi, et al., Characterization of Candida albicans epidermolytic proteases and their role in yeast-cell adherence to keratinocytes, Clinical and Experimental Dermatology, 15, 183-191 (1990).
Chakrabarti, et al.,In vitro proteinase production by Candida species, Mycopathologia, 114, 163-168 (1991).
De Bernardis, et al., Evidence for a Role for Secreted Aspartate Proteinase of Candida albicans in Vulvovaginal Candidiasis, J. of Infectious Diseases, 161, 1276-1283 (1990).
Cassone, et al., Evidence for a Correlation Between Proteinase Secretion and Vulvovaginal Candidosis, J. of Infectious Diseases, 156, 777-783 (1987).
Ruchel, et al., Candida acid proteinases, J. of Medical and Veterinary Mycology, 30, 123-132 (1992).
Segal, E., Chapters 5 & 6, pp. 49-76, CRC Press, 1994.
Sandovsky-Losica et al., Immun. Infect. Dis., vol. 3, pp. 155-159, 1993.
Goldman, R.C. et al., Infectious Agents and Disease, vol. 4, pp. 228-247, 1995.
Fusek, M. et al., Biochem., 1994, vol. 33, pp. 9791-9799.
Ruchel, R. et al., 261. Bakt, vol. 273, pp. 391-403, 1990.
Fallon Kimberly Ann
Huguenel Edward David
Tamburini Paul Perry
Bayer Corporation
Gray William F.
Housel James C.
Portner Ginny Allen
LandOfFree
Dissemination of fungal infections: animal model and method of p does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dissemination of fungal infections: animal model and method of p, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dissemination of fungal infections: animal model and method of p will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1513707